We consider the validation of prognostic diagnostic tests that predict two prognostic subgroups (high-risk vs low-risk) for a given disease or treatment. When comparing survival curves between two prognostic subgroups the possibility of misclassification arises, i.e. a patient predicted as high-risk might be de facto low-risk and vice versa. This is a fundamental difference from comparing survival curves between two populations (e.g. control vs treatment in RCT), where there is not an option of misclassification between members of populations. We show that there is a relationship between prognostic subgroups' survival estimates at a time point and positive and negative predictive values in the classification settings. Consequently, the prevalence needs to be taken into account when validating the survival of prognostic subgroups at a time point. Our findings question current methods of comparing survival curves between prognostic subgroups in the validation set because they do not take into account the survival rates of the population.
Introduction
The goal of personalised medicine is to apply treatments only to individuals who will benefit from them. This presumes that we have available clinical and genetic information about the patients as well as statistical methodology to identify a subgroup which benefits from a treatment. From the statistical point of view, the future of personalised medicine depends on how well we can separate a subgroup of patients that benefits from a treatment. Our starting point is a single survival population. Our goal is to use all available data about the patients to build a predictive model in order to find two sub-groups, one with better and the other with worse survival prognoses. However, in order to achieve the goal we need to have a set of well-defined statistics which measure, as accurately as possible, the differences between the subgroups' survival prognoses.
A common procedure when validating prognostic separation is to perform the same actions as when comparing two survival populations, i.e. to estimate survivor functions for each prognostic group with Kaplan-Meier (KM) survival curve [1] , to calculate hazard ratio (HR) [2] and to compare the curves with the log-rank test [3] .
Royston and Altman [4] say the following on this subject: "Kaplan-Meier survival curves for risk groups provide informal evidence of discrimination. The more widely separated are the curves, the better is the discrimination. A Kaplan-Meier graph for both datasets allows a visual comparison of discrimination between datasets. We strongly recommend producing such plots.". In Fig. 1 we show an example of KM survival curves for two prognostic subgroups as well as calculated HR and the p-value for the log-rank test.
Our thesis is that current statistical methods for comparing survival curves between two prognostic subgroups may be misleading because they do not take into account the survival rates of the population.
Methods
It is very important that we clearly define the terms we use. The survival population is a homogeneous population of individuals each having a "failure time". Let T be a non-negative random variable representing the "failure time" of an individual from the survival population. The survivor function S(t) = P({T>t}) is the probability that T exceeds the value t [5] [6] . In practice we usually do not know the survivor functions, but we are able to estimate them. We use the term survival curve when we refer to an estimate of a survivor function. The population survival rate at time To S(To) is the proportion of the population with "failure time" after To.
We use a predictive model to separate a survival population into two prognostic subgroups: high-risk and low-risk. In practice the prognostic sub-groups are usually created after dichotomising a prognostic index, a numerical output of a prognostic model [4] . We are interested in the process of external validation, which means assessing a model of prognostic separation already developed when applied to an independent dataset [4] . We refer to a dataset used in external validation as the validation dataset. In order to explain our point we will suppose that there is no censored data in our validation dataset, i.e. we know the exact failure time for each subject.
Estimating the survival of high-risk and low-risk patients at time To
To start with, we are interested in estimating the survival of high-risk and low-risk patients at time To, i.e. S HIGH-RISK (To) and S LOW-RISK (To). In the absence of censoring, we can estimate it for each prognostic subgroup as a ratio of the number of patients who had an event after To over the size of the subgroup in the validation dataset. It is important to understand that when we apply prognostic separation of a single population mistakes will occur. An individual who is in reality high-risk may be wrongly predicted as low-risk and vice versa. With a prognostic separation we have the possibility of misclassifying individuals, and we can introduce the following convention. Patients who had an event after To and who are predicted as low-risk would be true negatives (TN), while those who are predicted as high-risk would be false negatives (FN). Similarly, patients with an event before or equal to To who are predicted as high-risk would be true positives (TP), while those who are predicted as low-risk would be false positives(FP). Using this simple diagnostic test we can calculate sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) [7] [8] . We can estimate the sensitivity and specificity from a validation set, but without the knowledge of prevalence we are unable to estimate PPV or NPV [8] . The prevalence is the proportion of positive patients in the population, also known as the prior probability of being positive. It is a measure independent of the validation dataset. If, however, we know the prevalence then the predictive values would be estimated with the following equations [8] :
In our case then S HIGH-RISK (To) and S LOW-RISK (To) would be estimates of proportions of negative samples in the high-risk and low-risk prognostic subgroups, i.e.
And here we have a problem. Their estimates depend on the prevalence. In our case prevalence is the proportion of patients in the population who had an event before or equal to time To, i.e.
Therefore, we cannot estimate S HIGH-RISK (To) or S LOW-RISK (To) without the knowledge of the population survival rate at To. Consequently, we cannot use the naive estimates c/(c+d) and a/(a+b) as our estimates for S HIGH-RISK (To) and S LOW-RISK (To).
In survival settings the most common method of estimating survival at time To is to use Kaplan-Meier product-estimator [1] . However, in the absence of censoring, as we will show in our simulation example, the KM estimates for both prognostic subgroups at To are identical to the naive estimates. We thus conclude that in the absence of censoring we cannot use KM to estimate the survival of prognostic subgroups at To because it does not take into account the population survival rate at T=To.
Furthermore, as this holds for any time-point To, we also conclude that in the absence of censoring we cannot use KM curves to compare the survival of two prognostic subgroups.
Comparing survival curves of two prognostic subgroups
We argue that our conclusion holds when a validation dataset is with censored data and when we use estimates of survival curve other than KM In order to estimate the survival of high-risk and low-risk patients at time To we need to know the population survival rate at To, i.e. S(To). Furthermore, the survivalROC R package [9] [11] provides a way of estimating sensitivity and specificity at To using survival data. Therefore, by knowing prevalence (Eq5), and with estimated sensitivity and specificity at To, we can then apply equations (Eq1)-(Eq4) to calculate S HIGH-RISK (To) and S LOW-RISK (To).
Difference in the survival of high-risk and low-risk patients at time To
We now examine whether the difference between estimates of the survival of highrisk and low-risk patients at time To depends on the population survival rate at To. In the equation Eq6 we show that it clearly does. 
Results
We created an example with simulated survival dataset without any censored data.
Our intention is to analyse the effect of various population survival rates on our estimates of the 5-year survival of high-risk and low-risk patients. Later we use the same dataset and randomly transform 30% of it into censored data. We then apply the same analysis to it.
Simulated example
We generated samples of 400 high-risk and 400 low-risk patients with different exponential survival distributions and without any censored data. KM graphs for both prognostic subgroups are shown in Fig.3 Table 3 
Censored data
We modified the simulated dataset so that it contains censored data. We randomly selected 30% of patients in both prognostic subgroups to be censored. For each censored patient we assigned its last known survival time to be a random number between 0 and its actual "failure" time. KM graphs for both prognostic subgroups are shown in Fig.4 . Using the KM product estimator we calculated that S HIGH-RISK (5 years)=0.2463 while S LOW-RISK (5 years)=0.4238. We calculated specificity and sensitivity at 5 years (5-year-spec=0.6374, 5-year-sens=0.5706) with the survivalROC R package. Similar as in Table 3 , we show in Table 4 
Discussion
In practice we have never worked with a validation dataset that does not have censored data. Consequently, we have never had a chance to use naive estimates nor to create a confusion matrix for a particular time-point as described above. The most common method for estimating survival with censored data is to use KM estimates.
However, even though with censored data we cannot clearly show the close relationship between KM and naive estimates, we argue that if the relationships exist in the non-censored case then they must exist in the censored.
In theory an external validation dataset ought to be representative of the population, but in practice it seldom is, or it is difficult to prove that it is. If we want to compare survival curves of prognostic subgroups, we have shown that the external validation dataset ought to have the same survival rates as the population for all time-points.
Furthermore, we have shown that without prior knowledge of the population survival rates we cannot estimate survival curves of prognostic sub-groups. As a consequence, Kaplan-Meier survival curves for prognostic sub-groups, as well as their hazard ratio and the p-value for the log-rank test, may be wrong.
We disagree with the strong recommendation by Royston and Altman [4] to produce a plot with KM survival curves for both prognostic subgroups as a visual comparison of discrimination between them. We think the plot might be an inaccurate representation of the discrimination between prognostic subgroups. In Table 5 we show the differences in the 5-year survival between prognostic subgroups for various combinations of specificity, sensitivity, 5-year population survival rate and 5-year survival rate in the validation dataset. The "5-year survival difference" is calculated taking into account the 5-year population survival rate, while the "naive 5-year survival difference" is based on the 5-year survival rate in the validation dataset. It shows that we can overestimate as well as underestimate the difference in the 5-year survival between prognostic subgroups if the 5-year population survival rate is not taken into account.
In our opinion, the way forward is not to compare survival curves of prognostic subgroups but to report their survival at specific time-points. They would be calculated using the population survival rate, specificity and sensitivity (Eq5). If no historical data exist from which one could generate a population survival rate, then one would report specificity and sensitivity at specific time-points.
Conclusion
We have shown that we are not able to estimate the survival of prognostic subgroups without the knowledge of population survival rates. We have shown that the relationship is the same as between negative and positive predictive values and prevalence. Tables   Table 1 -A contingency table between positive and negative patients and  predicted low-risk and high-risk patients   Table 2 -A confusion matrix between positive and negative patients and predicted low-risk and high-risk patients in the simulated example 
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